Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination
highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol
are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in
combination with current nucleoside reverse transcriptase inhibitors (NRTIs).